Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2005 Nov;5(11):1475-89.

Meningococcal conjugate vaccines.

Author information

1
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York 14642, USA. Michael_pichichero@urmc.rochester.edu

Abstract

Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do not produce a herd effect. Monovalent and quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccines have recently been licensed and endorsed for use in infants, children, adolescents and adults in various countries. Among the key features of the new meningococcal conjugate vaccines are stimulation of both B cell-dependent and T cell-dependent immune responses, induction of immunological memory and booster effects, longer-term protection, reduction of nasopharyngeal carriage of N. meningitidis, and herd immunity. Large, randomised, double-blind studies in adults, adolescents, children and infants have demonstrated the immunogenicity and safety of the new meningococcal conjugate vaccine formulations.

PMID:
16255651
DOI:
10.1517/14712598.5.11.1475
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center